Bafna Pharmaceuticals Limited
NSE: BAFNAPH
NSE
99.48
9.04 (10.00%)
Prev Close
90.44
Open Price
93.8
Volume
66,960
Today Low / High
92 / 99.48
52 WK Low / High
69 / 99.48
Range
95 - 104
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 99.48, with a change of 9.04 (9.99558%). The expected target range on the NSE is between 95 - 104. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
12 Aug
94.67
-4.47%
11 Aug
87.70
4.80%
08 Aug
85.99
-0.70%
07 Aug
78.18
4.09%
06 Aug
84.90
-2.07%
05 Aug
89.16
-4.70%
04 Aug
85.18
4.16%
01 Aug
87.70
-2.36%
31 Jul
89.49
-2.32%
30 Jul
87.51
0.63%
29 Jul
87.21
3.16%
28 Jul
93.60
-4.71%
25 Jul
88.96
1.19%
24 Jul
90.63
-2.01%
23 Jul
90.50
-1.46%
22 Jul
89.21
-0.24%
Bafna Pharmaceuticals Limited Graph
Bafna Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Bafna Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 99.48, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 99.48 | 100.47 | 90.43 - 110.52 |
| 101.47 | 81.18 - 121.76 | ||
| 102.46 | 71.73 - 133.20 | ||
| Bearish Scenario | 99.48 | 98.49 | 88.64 - 108.33 |
| 97.49 | 77.99 - 116.99 | ||
| 96.50 | 67.55 - 125.44 |
Overview of Bafna Pharmaceuticals Limited
ISIN
INE878I01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
5,537
Market Cap
2,139,475,772
Last Dividend
0
Official Website
IPO Date
2012-11-12
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of BAFNAPH
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2013-09-19 | September 19, 13 | 0.6 | 0.06 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 145.86 Cr | 128.98 Cr | 16.88 Cr | 0.1157 | 0.00 Cr | 0.00 Cr | 6.29 Cr | 4.15 Cr | 1.75 | 11.77 Cr | 0.0285 |
| 2024-03-31 | 152.47 Cr | 107.25 Cr | 45.22 Cr | 0.2966 | 1.54 Cr | 19.31 Cr | 23.77 Cr | 7.35 Cr | 3.11 | 14.63 Cr | 0.0482 |
| 2023-03-31 | 115.35 Cr | 76.59 Cr | 38.76 Cr | 0.3360 | 0.72 Cr | 1.48 Cr | 11.77 Cr | 11.34 Cr | 4.79 | 18.99 Cr | 0.0983 |
| 2022-03-31 | 85.14 Cr | 51.54 Cr | 33.60 Cr | 0.3946 | 1.47 Cr | 1.99 Cr | 6.64 Cr | 5.22 Cr | 2.21 | 11.23 Cr | 0.0613 |
| 2021-03-31 | 71.22 Cr | 62.23 Cr | 8.98 Cr | 0.1261 | 1.36 Cr | 0.72 Cr | 6.14 Cr | 5.83 Cr | 2.46 | 10.39 Cr | 0.0818 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3.43 Cr | 153.08 Cr | 66.36 Cr | 84.8065 Cr | 28.20 Cr | 24.77 Cr | 28.09 Cr | 66.09 Cr | 0.00 Cr | 0.00 Cr | 0.81 Cr | 51.8517 Cr |
| 2024-03-31 | 1.40 Cr | 147.68 Cr | 66.84 Cr | 80.8390 Cr | 24.39 Cr | 22.99 Cr | 29.64 Cr | 50.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 54.0830 Cr |
| 2023-03-31 | 7.81 Cr | 129.58 Cr | 56.13 Cr | 73.4546 Cr | 22.92 Cr | 15.11 Cr | 22.22 Cr | 40.23 Cr | 0.00 Cr | 1.22 Cr | 0.00 Cr | 46.4763 Cr |
| 2022-03-31 | 0.02 Cr | 90.14 Cr | 28.18 Cr | 61.9637 Cr | 11.06 Cr | 11.04 Cr | 20.28 Cr | 38.85 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 22.0127 Cr |
| 2021-03-31 | 0.75 Cr | 86.47 Cr | 29.69 Cr | 56.7711 Cr | 15.79 Cr | 12.25 Cr | 15.44 Cr | 36.80 Cr | 0.89 Cr | 0.00 Cr | 0.00 Cr | 24.3088 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 19.5290 Cr | -21.3016 Cr | 3.8093 Cr | -2.3307 Cr | 0.0000 Cr | 3.4327 Cr | -21.8597 Cr | 4.1525 Cr | 3.8093 Cr | 0.0000 Cr | 1.1802 Cr |
| 2024-03-31 | 9.4848 Cr | -15.0536 Cr | -0.8454 Cr | -6.3634 Cr | -6.4134 Cr | 1.3960 Cr | -15.5782 Cr | 7.3479 Cr | 1.4654 Cr | 0.0000 Cr | -7.4231 Cr |
| 2023-03-31 | 4.9525 Cr | -7.4932 Cr | 10.1771 Cr | -3.2661 Cr | 7.6364 Cr | 7.8094 Cr | -6.7187 Cr | 11.7691 Cr | 11.8645 Cr | 0.0000 Cr | -1.9391 Cr |
| 2022-03-31 | 9.7283 Cr | -6.5442 Cr | -4.8148 Cr | 2.1871 Cr | -1.6307 Cr | 0.1730 Cr | -7.5412 Cr | 5.2163 Cr | -4.7266 Cr | 0.0000 Cr | -4.8372 Cr |
| 2021-03-31 | -13.6089 Cr | -5.3454 Cr | 12.2798 Cr | -19.7036 Cr | -6.6764 Cr | 1.8037 Cr | -6.0947 Cr | 5.8267 Cr | 12.3684 Cr | 0.0000 Cr | -4.0309 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 39.06 Cr | 32.38 Cr | 6.68 Cr | 0.1710 | 2.90 Cr | 1.31 Cr | 0.55 | 2.35 Cr | 0.0336 |
| 2024-12-31 | 33.19 Cr | 23.63 Cr | 9.56 Cr | 0.2881 | 1.41 Cr | 0.95 Cr | 0.40 | 3.24 Cr | 0.0286 |
| 2024-09-30 | 40.32 Cr | 27.76 Cr | 12.57 Cr | 0.3117 | 2.22 Cr | 2.62 Cr | 1.11 | 4.82 Cr | 0.0649 |
| 2024-06-30 | 33.29 Cr | 31.68 Cr | 1.61 Cr | 0.0484 | -0.23 Cr | -0.72 Cr | -0.31 | 1.37 Cr | -0.0217 |
| 2024-03-31 | 41.40 Cr | 34.89 Cr | 6.51 Cr | 0.1573 | 1.62 Cr | 1.46 Cr | 0.62 | 3.40 Cr | 0.0352 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3.43 Cr | 0.00 Cr | 3.43 Cr | 40.20 Cr | 28.09 Cr | 84.73 Cr | 66.09 Cr | 153.08 Cr | 66.36 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -82.75 Cr |
| 2024-09-30 | 1.31 Cr | 0.01 Cr | 1.32 Cr | 0.00 Cr | 27.47 Cr | 74.61 Cr | 55.53 Cr | 134.16 Cr | 51.41 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 1.40 Cr | 0.00 Cr | 0.00 Cr | 1.40 Cr | 0.00 Cr | 0.00 Cr | -80.84 Cr |
| 2024-03-31 | 1.40 Cr | 0.70 Cr | 1.40 Cr | 45.39 Cr | 29.64 Cr | 94.47 Cr | 50.71 Cr | 147.68 Cr | 66.84 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 0.95 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 2.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -0.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 1.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | -2.94 Cr | 2.54 Cr | 0.00 Cr | 0.00 Cr | 2.54 Cr | 10.41 Cr | 7.86 Cr | 0.00 Cr | 2.54 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-08-26 | August 26, 19 | 1:10 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,640.90 | ₹3,936,978,552,000.00 | ₹1,313,620.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,100.50 | ₹1,619,493,634,500.00 | ₹394,932.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,617.80 | ₹1,224,426,321,000.00 | ₹287,405.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,253.40 | ₹1,043,245,022,805.00 | ₹1,191,889.00 |
| Mankind Pharma Limited | MANKIND | ₹2,466.00 | ₹1,017,789,122,160.00 | ₹376,033.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹988.60 | ₹994,758,978,000.00 | ₹1,911,246.00 |
| Lupin Limited | LUPIN | ₹1,989.80 | ₹908,835,180,600.00 | ₹875,748.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,388.50 | ₹644,276,002,500.00 | ₹899,623.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,078.20 | ₹626,220,716,400.00 | ₹444,368.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,029.30 | ₹572,670,489,300.00 | ₹466,363.00 |
| Laurus Labs Limited | LAURUSLABS | ₹863.15 | ₹465,949,948,750.00 | ₹2,817,579.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹986.05 | ₹377,230,198,238.00 | ₹177,879.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,364.60 | ₹346,204,478,400.00 | ₹113,365.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,671.70 | ₹333,791,511,200.00 | ₹40,260.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,715.50 | ₹268,163,529,000.00 | ₹62,276.00 |
| Piramal Enterprises Limited | PEL | ₹1,127.20 | ₹255,511,441,600.00 | ₹243,681.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,501.60 | ₹243,978,466,400.00 | ₹325,967.00 |
| Eris Lifesciences Limited | ERIS | ₹1,674.80 | ₹228,119,483,600.00 | ₹42,022.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,416.50 | ₹210,412,500,000.00 | ₹34,705.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹941.00 | ₹184,965,783,000.00 | ₹25,900.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,077.50 | ₹171,625,277,500.00 | ₹132,577.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,018.00 | ₹167,019,638,200.00 | ₹23,483.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,156.90 | ₹163,949,635,730.00 | ₹164,102.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹904.25 | ₹161,960,217,500.00 | ₹516,819.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹460.35 | ₹111,701,165,400.00 | ₹778,530.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,182.50 | ₹102,625,790,500.00 | ₹13,202.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹906.20 | ₹88,618,113,580.00 | ₹114,891.00 |
| Strides Pharma Science Limited | STAR | ₹867.30 | ₹79,941,382,710.00 | ₹568,013.00 |
| FDC Limited | FDC | ₹483.20 | ₹78,669,792,000.00 | ₹76,497.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹790.45 | ₹71,642,135,379.00 | ₹1,229,147.00 |
| Innova Captab Limited | INNOVACAP | ₹902.00 | ₹51,616,886,860.00 | ₹24,559.00 |
| Suven Life Sciences Limited | SUVEN | ₹232.25 | ₹50,647,686,500.00 | ₹235,893.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹142.28 | ₹46,172,990,160.00 | ₹192,243.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹488.05 | ₹44,544,323,500.00 | ₹79,719.00 |
| Sequent Scientific Limited | SEQUENT | ₹171.51 | ₹42,934,955,850.00 | ₹221,470.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹768.10 | ₹38,957,340,710.00 | ₹102,241.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,281.60 | ₹37,735,382,400.00 | ₹9,674.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹513.80 | ₹36,174,500,040.00 | ₹45,592.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹356.70 | ₹35,769,162,600.00 | ₹36,115.00 |
| Hikal Limited | HIKAL | ₹255.65 | ₹31,521,900,650.00 | ₹589,191.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹605.30 | ₹29,147,010,900.00 | ₹54,573.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹93.23 | ₹27,365,522,210.00 | ₹1,598,864.00 |
| Indoco Remedies Limited | INDOCO | ₹293.70 | ₹27,093,208,230.00 | ₹138,144.00 |
| Alembic Limited | ALEMBICLTD | ₹105.19 | ₹27,010,898,475.00 | ₹451,825.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹47.31 | ₹25,923,703,740.00 | ₹3,167,804.00 |
Key Executives
Whole-Time Director of Quality
Mr. Vinayak Dinesh Dendukuri
Gender: male
Year Born: 1987
Executive Chairman
Ms. Shanmugam Hemalatha
Gender: female
Year Born: 1975
Company Secretary & Compliance Officer
Mr. A. Mohanachandran
Gender: male
Year Born:
Chief Executive Officer
Mr. Bansilal Mahaveer Chand Bafna
Gender: male
Year Born: 1961
Chief Financial Officer
Mr. Melagiri Sridhar
Gender: male
Year Born: 1968
FAQs about Bafna Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Bansilal Mahaveer Chand Bafna.
What is the current market price of the stock?
The current price is ₹90.44.
What is the 52-week price range?
The range is ₹69-94.99.
What is the market capitalization of the company?
The market capitalization is ₹213.95 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 51.60.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Bafna Pharmaceuticals Limited (ISIN: INE878I01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹213.95 crores and an average daily volume of 5,537 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.